Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Treatment strategies for cHL patients after auto-HSCT

Anna Sureda • 24 Aug 2020
EBMT 2020
Hodgkin Lymphoma Lymphoma Brentuximab vedotin CAR-T Pembrolizumab

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses different treatment strategies for patients with classical Hodgkin lymphoma (cHL) that relapse or progress after autologous-hematopoietic stem cell transplant (auto-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anna Sureda

1:54
Looking forward to the 50th Annual Meeting of the EBMT
Anna Sureda • 7 Mar 2024
3:32
The risk of secondary malignancies following CAR T-cell therapy: current evidence
Anna Sureda • 7 Mar 2024
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:16
The success of the EBMT-EHA 6th European CAR T-cell Meeting
Anna Sureda • 7 Mar 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals